Skip to main content
SpringerLink
Log in

Allogeneic Hematopoietic Stem Cell Transplantation for AML

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 451 Accesses

Abstract

Acute myeloid leukemia (AML) is the main indication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Even with the great advances of targeted drugs in last decades, allo-HSCT is still the most powerful curative method. The major advances in this field include several aspects. First, the accurate diagnosis and the dynamic minimal residual disease (MRD) monitoring lead to more precise risk stratification like who will benefit from allo-HSCT and non-transplantation, therefore redefined the allo-HSCT indication. Second, the great advance in allo-HSCT has further expanded the transplant-eligible population, including less toxic conditioning regimen, better prophylaxis of GVHD, and infection. Third, the advances in alternative donor transplantation have led to an era of “everyone has donor”, and even challenged the classical rule “matched sibling donor is always preferred over alternative donor”.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010. https://doi.org/10.1038/nrdp.2016.10.

    Article  PubMed  Google Scholar 

  2. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. https://doi.org/10.1016/S0140-6736(18)31041-9.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11(1):33. https://doi.org/10.1186/s13045-018-0564-x.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. https://doi.org/10.1182/blood-2016-08-733196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Qin YZ, Zhu HH, Jiang Q, Xu LP, Jiang H, Wang Y, et al. Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer J. 2018b;8(8):76. https://doi.org/10.1038/s41408-018-0116-1.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yang L, Chen WM, Dao FT, Zhang YH, Wang YZ, Chang Y, et al. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. Cancer Med. 2019;8(12):5459–67. https://doi.org/10.1002/cam4.2422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, et al. High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy. Med Sci Monit. 2018a;24:758–67. https://doi.org/10.12659/msm.905903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kong J, Zhao XS, Qin YZ, Zhu HH, Jia JS, Jiang Q, et al. The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2018;59(4):967–72. https://doi.org/10.1080/10428194.2017.1352091.

    Article  CAS  PubMed  Google Scholar 

  9. Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131(12):1275–91. https://doi.org/10.1182/blood-2017-09-801498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chang YJ, Zhao XS, Wang Y, Liu YR, Xu LP, Zhang XH, et al. Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. Am J Hematol. 2017b;92(12):E659–E61. https://doi.org/10.1002/ajh.24910.

    Article  CAS  PubMed  Google Scholar 

  11. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056–62. https://doi.org/10.1182/blood-2012-11-468348.

    Article  CAS  PubMed  Google Scholar 

  12. Deng DX, Zhu HH, Liu YR, Chang YJ, Ruan GR, Jia JS, et al. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. Leuk Lymphoma. 2019;60(9):2181–9. https://doi.org/10.1080/10428194.2019.1576868.

    Article  CAS  PubMed  Google Scholar 

  13. Gao MG, Ruan GR, Chang YJ, Liu YR, Qin YZ, Jiang Q, et al. The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. Ann Hematol. 2020b;99(1):73–82. https://doi.org/10.1007/s00277-019-03861-1.

    Article  CAS  PubMed  Google Scholar 

  14. Xhaard A, Cunha R, Busson M, Robin M, Dhedin N, Coman T, et al. Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after Allo-HSCT. Blood Adv. 2017;1(18):1409–13. https://doi.org/10.1182/bloodadvances.2017008094.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, et al. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplant. 2021;56(2):387–94. https://doi.org/10.1038/s41409-020-01032-9.

    Article  PubMed  Google Scholar 

  16. ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015;170(4):574–83. https://doi.org/10.1111/bjh.13476.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21(8):1479–87. https://doi.org/10.1016/j.bbmt.2015.04.004.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9. https://doi.org/10.1182/blood-2005-05-2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index in Nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(10):1744–8. https://doi.org/10.1016/j.bbmt.2017.06.005.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol. 2013;88(6):497–502. https://doi.org/10.1002/ajh.23443.

    Article  PubMed  Google Scholar 

  21. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249–56. https://doi.org/10.1200/JCO.2013.53.8157.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749–56. https://doi.org/10.1038/bmt.2011.110.

    Article  CAS  PubMed  Google Scholar 

  23. Wang HT, Chang YJ, Xu LP, Liu DH, Wang Y, Liu KY, et al. EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Bone Marrow Transplant. 2014a;49(7):927–33. https://doi.org/10.1038/bmt.2014.80.

    Article  PubMed  Google Scholar 

  24. Chang YJ, Wang HT, Xu LP, Wang Y, Liu KY, Zhang XH, et al. Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leuk Lymphoma. 2016;57(9):2133–9. https://doi.org/10.3109/10428194.2015.1124990.

    Article  PubMed  Google Scholar 

  25. Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant. 2020;55(8):1604–13. https://doi.org/10.1038/s41409-020-0826-4.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. https://doi.org/10.1001/jama.2009.813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, Zhang XH, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood. 2012;119(23):5584–90. https://doi.org/10.1182/blood-2011-11-389809.

    Article  CAS  PubMed  Google Scholar 

  28. Lv M, Wang Y, Chang YJ, Zhang XH, Xu LP, Jiang Q, et al. Myeloablative Haploidentical transplantation is superior to chemotherapy for patients with intermediate-risk acute Myelogenous leukemia in first complete remission. Clin Cancer Res. 2019;25(6):1737–48. https://doi.org/10.1158/1078-0432.CCR-18-1637.

    Article  CAS  PubMed  Google Scholar 

  29. Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I, et al. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Haematologica. 2016;101(8):e352–4. https://doi.org/10.3324/haematol.2015.140509.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Sun YQ, Chang YJ, Huang XJ. Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Rev Hematol. 2018;11(4):273–84. https://doi.org/10.1080/17474086.2018.1447379.

    Article  CAS  PubMed  Google Scholar 

  31. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs. identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956–62. https://doi.org/10.1182/blood-2015-02-627786.

    Article  CAS  PubMed  Google Scholar 

  32. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467–76. https://doi.org/10.1158/1078-0432.CCR-15-2335.

    Article  CAS  PubMed  Google Scholar 

  33. Wang Y, Wu DP, Liu QF, Xu LP, Liu KY, Zhang XH, et al. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants. Leukemia. 2018;32(2):492–8. https://doi.org/10.1038/leu.2017.199.

    Article  CAS  PubMed  Google Scholar 

  34. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011;17(6):821–30. https://doi.org/10.1016/j.bbmt.2010.08.023.

    Article  PubMed  Google Scholar 

  35. Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017a;10(1):134. https://doi.org/10.1186/s13045-017-0502-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Chang YJ, Wang Y, Xu LP, Zhang XH, Chen H, Chen YH, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;13(1):27. https://doi.org/10.1186/s13045-020-00860-y.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Liu J, Ma R, Liu YR, Xu LP, Zhang XH, Chen H, et al. The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant. 2019;54(4):567–77. https://doi.org/10.1038/s41409-018-0300-8.

    Article  PubMed  Google Scholar 

  38. Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201–12. https://doi.org/10.1016/S1470-2045(20)30455-1.

    Article  CAS  PubMed  Google Scholar 

  39. Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002. https://doi.org/10.1200/JCO.19.03345.

    Article  PubMed  Google Scholar 

  40. Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, et al. Effect of rhG-CSF combined with Decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020a;38(36):4249–59. https://doi.org/10.1200/JCO.19.03277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Qin YZ, Wang Y, Xu LP, Zhang XH, Chen H, Han W, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017;10(1):44. https://doi.org/10.1186/s13045-017-0414-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014b;124(12):1880–6. https://doi.org/10.1182/blood-2014-03-563403.

    Article  CAS  PubMed  Google Scholar 

  43. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256–62. https://doi.org/10.1182/blood-2011-09-380386.

    Article  CAS  PubMed  Google Scholar 

  44. Yan CH, Wang Y, Wang JZ, Chen YH, Chen Y, Wang FR, et al. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol. 2016;9(1):87. https://doi.org/10.1186/s13045-016-0319-5.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Mo XD, Wang Y, Zhang XH, Xu LP, Yan CH, Chen H, et al. Interferon-alpha is effective for treatment of minimal residual disease in patients with t(8;21) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: results of a prospective registry study. Oncologist. 2018;23(11):1349–57. https://doi.org/10.1634/theoncologist.2017-0692.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Interferon-alpha: a potentially effective treatment for minimal residual disease in acute leukemia/Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(11):1939–47. https://doi.org/10.1016/j.bbmt.2015.06.014.

    Article  CAS  PubMed  Google Scholar 

  47. Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. IFN-alpha is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study. Biol Blood Marrow Transplant. 2017;23(8):1303–10. https://doi.org/10.1016/j.bbmt.2017.04.023.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China

    Yu-Qian Sun & Xiao-Jun Huang

Authors
  1. Yu-Qian Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Jun Huang .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sun, YQ., Huang, XJ. (2023). Allogeneic Hematopoietic Stem Cell Transplantation for AML. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation